Effect of Hyaluronic Acid on Perimplantitis
Primary Purpose
Peri-Implantitis
Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Hyaluronic Acid
Hydroxypropyl Guar
Sponsored by
About this trial
This is an interventional treatment trial for Peri-Implantitis focused on measuring Peri-Implantitis, Dental Implants, Hyaluronic Acid, Clinical Trial
Eligibility Criteria
Inclusion Criteria:
- Implants with at least one year of functional load.
- Implants diagnosed with peri-implantitis according to the criteria of the Association of Dental Implantology.
Exclusion Criteria:
- Previous peri-implantitis treatment.
- Pregnancy or breast-feeding.
- Neoplastic disease.
- Antibiotic treatment during the previous month.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Sham Comparator
No Intervention
Arm Label
Test Group
Control 1 Group
Control 2 Group
Arm Description
Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
Hydroxypropyl guar based gel, without any biological effect.
No gel application, only standard perimplantitis treatment.
Outcomes
Primary Outcome Measures
Peri-implant probing depth
Probing depth (mm) assessed by periodontal probe.
Peri-implant attachment level
Probing attachment level (mm) calculated using probing depth and exposed implant threads.
Peri-implant bleeding
Bleeding on probing expressed as % of bleeding implants in each group.
Marginal Bone level
Alveolar bone level assesed in periapical digital radiographs by image processing software (ImageJ).
Peri-implant crevicular fluid cytokines.
Inflammatory cytokines (IL1B and TNFa) measured in Peri-implant crevicular fluid by ELISA.
Secondary Outcome Measures
Full Information
NCT ID
NCT03157193
First Posted
May 15, 2017
Last Updated
May 16, 2017
Sponsor
Universidad de Granada
Collaborators
Ricerfarma S.r.l
1. Study Identification
Unique Protocol Identification Number
NCT03157193
Brief Title
Effect of Hyaluronic Acid on Perimplantitis
Official Title
Effect of Hyaluronic Acid on Peri-implant Pathology: A Double-blind, Randomized, Controlled Clinical Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
September 2014 (Actual)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
December 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universidad de Granada
Collaborators
Ricerfarma S.r.l
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The effect of the hyaluronic acid treatment on peri-implantitis has not been tested. The aim was to analyze the effect of a hyaluronic acid-containing gel on the clinical variables and the expression of biochemical inflammatory markers in the crevicular fluid of implants receiving perimplantitis treatment.
Detailed Description
The aim was to analyze the effect of a hyaluronic acid-containing gel on the clinical variables and the expression of biochemical inflammatory markers in the crevicular fluid of implants receiving perimplantitis treatment.
A randomized, controlled, double-blind clinical trial was designed on 100 perimplantitis affected implants placed in 61 subjects. Inclusion criteria were implants with at least 1 year of functional loading and with diagnosis of perimplantitis following the criteria from the Association of Dental Implantology. All implant received perimplantitis treatment. Each patient was randomly assigned to receive a gel containing 0.8% HA (Test group), a gel without HA (Placebo group) or no gel treatment (Control group). After a first gel application at baseline, test and placebo patients performed gel applications at home 3 times/day for 45 days. Clinical variables of each implant were recorded at baseline, 45 and 90 days (probing depth, attachment loss, bleeding). Intraoral radiographs of each implants were performed to measure marginal bone level. Peri-implant crevicular fluid was collected from each implant at baseline and after 45 days of treatment, to assess IL-1β and TNFα levels by ELISA technique. Clustering analysis, considering multiple implants within each patient, was performed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peri-Implantitis
Keywords
Peri-Implantitis, Dental Implants, Hyaluronic Acid, Clinical Trial
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
61 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Test Group
Arm Type
Experimental
Arm Description
Hyaluronic acid gel 0.2% at baseline and later home applications by the patients during 45 days.
Arm Title
Control 1 Group
Arm Type
Sham Comparator
Arm Description
Hydroxypropyl guar based gel, without any biological effect.
Arm Title
Control 2 Group
Arm Type
No Intervention
Arm Description
No gel application, only standard perimplantitis treatment.
Intervention Type
Drug
Intervention Name(s)
Hyaluronic Acid
Other Intervention Name(s)
HA
Intervention Description
Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
Intervention Type
Drug
Intervention Name(s)
Hydroxypropyl Guar
Other Intervention Name(s)
Control 1
Intervention Description
Hydroxypropyl Guar gel application as sham comparator
Primary Outcome Measure Information:
Title
Peri-implant probing depth
Description
Probing depth (mm) assessed by periodontal probe.
Time Frame
Baseline, change at 45 days and at 90 days.
Title
Peri-implant attachment level
Description
Probing attachment level (mm) calculated using probing depth and exposed implant threads.
Time Frame
Baseline, change at 45 days and at 90 days.
Title
Peri-implant bleeding
Description
Bleeding on probing expressed as % of bleeding implants in each group.
Time Frame
Baseline, change at 45 days and at 90 days.
Title
Marginal Bone level
Description
Alveolar bone level assesed in periapical digital radiographs by image processing software (ImageJ).
Time Frame
Baseline, change at 45 days and at 90 days.
Title
Peri-implant crevicular fluid cytokines.
Description
Inflammatory cytokines (IL1B and TNFa) measured in Peri-implant crevicular fluid by ELISA.
Time Frame
Baseline and change at 45 days.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Implants with at least one year of functional load.
Implants diagnosed with peri-implantitis according to the criteria of the Association of Dental Implantology.
Exclusion Criteria:
Previous peri-implantitis treatment.
Pregnancy or breast-feeding.
Neoplastic disease.
Antibiotic treatment during the previous month.
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
33634616
Citation
Sanchez-Fernandez E, Magan-Fernandez A, O'Valle F, Bravo M, Mesa F. Hyaluronic acid reduces inflammation and crevicular fluid IL-1beta concentrations in peri-implantitis: a randomized controlled clinical trial. J Periodontal Implant Sci. 2021 Feb;51(1):63-74. doi: 10.5051/jpis.1903660183.
Results Reference
derived
Learn more about this trial
Effect of Hyaluronic Acid on Perimplantitis
We'll reach out to this number within 24 hrs